Anacor Pharmaceuticals, Inc. (ANAC): Keith R Leonard , director of Anacor Pharmaceuticals, Inc. sold 9,000 shares on May 23, 2016. The Insider selling transaction was reported by the company on May 24, 2016 to the Securities and Exchange Commission. The shares were sold at $99.70 per share for a total value of $897,300.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Anders D Hove (director) sold 353,881 shares at $99.65 per share price.On Apr 29, 2016, Ryan T Sullivan (EVP and General Counsel) sold 3,125 shares at $66.33 per share price.Also, On Mar 23, 2016, Paul L Berns (President and CEO) sold 37,500 shares at $60.17 per share price.On Mar 4, 2016, Vincent P Ippolito (EVP & Chief Commercial Officer) sold 9,000 shares at $63.72 per share price.
Anacor Pharmaceuticals Inc: On Friday, May 20, 2016 heightened volatility was witnessed in Anacor Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $99.52 and hit $99.97 on the upside , eventually ending the session at $99.66, with a gain of 0.17% or 0.17 points. The heightened volatility saw the trading volume jump to 33,83,392 shares. The 52-week high of the share price is $156.925 and the company has a market cap of $4,522,371 M . The 52-week low of the share price is at $52.
Company has been under the radar of several Street Analysts.Anacor Pharmaceuticals Inc is Downgraded by Mizuho to Neutral and the brokerage firm has set the Price Target at $99.25. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 18, 2016.Anacor Pharmaceuticals Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 148 from a previous price target of $152 . The Rating was issued on May 3, 2016.Anacor Pharmaceuticals Inc is Initiated by Mizuho to Buy and the brokerage firm has set the Price Target at $103. The Rating was issued on Mar 11, 2016.
Anacor Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on discovering developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company’s product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development which include AN3365. The Company’s compound AN5568 (SCYX-7158) is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).